VICTORIA
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multicenter pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator vericiguat (BAY 1021189) in patients with heart failure and reduced ejection fraction (HFrEF) -VerICiguaT glObal study in patients with HF and Reduced ejectIon frAction (VICTORIA)
- Stage
- klaar
- Medicine
- Vericiguat
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 6 December 2016
- Last Patient In
- 31 December 2018
- Last Patient Last Visit
- 28 August 2019
National Lead
